A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine...

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2018 Jul 4

PMID 29967804

Citations 10

Authors

Lesley C Dupuy

Michelle J Richards

Brian D Livingston

Drew Hannaman

Connie S Schmaljohn

Affiliations

Soon will be listed here.

Abstract

There remains a need for vaccines that can safely and effectively protect against the biological threat agents Venezuelan (VEEV), western (WEEV), and eastern (EEEV) equine encephalitis virus. Previously, we demonstrated that a VEEV DNA vaccine that was optimized for increased antigen expression and delivered by intramuscular (IM) electroporation (EP) elicited robust and durable virus-specific antibody responses in multiple animal species and provided complete protection against VEEV aerosol challenge in mice and nonhuman primates. Here, we performed a comparative evaluation of the immunogenicity and protective efficacy of individual optimized VEEV, WEEV, and EEEV DNA vaccines with that of a 1 : 1 : 1 mixture of these vaccines, which we have termed the 3-EEV DNA vaccine, when delivered by IM EP. The individual DNA vaccines and the 3-EEV DNA vaccine elicited robust and durable virus-specific antibody responses in mice and rabbits and completely protected mice from homologous VEEV, WEEV, and EEEV aerosol challenges. Taken together, the results from these studies demonstrate that the individual VEEV, WEEV, and EEEV DNA vaccines and the 3-EEV DNA vaccine delivered by IM EP provide an effective means of eliciting protection against lethal encephalitic alphavirus infections in a murine model and represent viable next-generation vaccine candidates that warrant further development.

Citing Articles

Syrian Hamsters Model Does Not Reflect Human-like Disease after Aerosol Exposure to Encephalitic Alphaviruses.

Gardner C, Erwin-Cohen R, Lewis B, Bakken R, Honnold S, Glass P Methods Protoc. 2024; 7(3).

PMID: 38804336 PMC: 11130913. DOI: 10.3390/mps7030042.

Designing a Multiepitope Vaccine against Eastern Equine Encephalitis Virus: Immunoinformatics and Computational Approaches.

Nguyen T, Kim H ACS Omega. 2024; 9(1):1092-1105.

PMID: 38222668 PMC: 10785064. DOI: 10.1021/acsomega.3c07322.

Developing a Prototype Pathogen Plan and Research Priorities for the Alphaviruses.

Powers A, Williamson L, Carnahan R, Crowe Jr J, Hyde J, Jonsson C J Infect Dis. 2023; 228(Suppl 6):S414-S426.

PMID: 37849399 PMC: 11007399. DOI: 10.1093/infdis/jiac326.

Vaccine elicitation and structural basis for antibody protection against alphaviruses.

Sutton M, Pletnev S, Callahan V, Ko S, Tsybovsky Y, Bylund T Cell. 2023; 186(12):2672-2689.e25.

PMID: 37295404 PMC: 10411218. DOI: 10.1016/j.cell.2023.05.019.

A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge.

Suschak J, Bixler S, Badger C, Spik K, Kwilas S, Rossi F NPJ Vaccines. 2022; 7(1):46.

PMID: 35459271 PMC: 9033795. DOI: 10.1038/s41541-022-00469-x.

References

Parker M, Buckley M, Melanson V, Glass P, Norwood D, Hart M . Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection. J Virol. 2010; 84(24):12683-90. PMC: 3004303. DOI: 10.1128/JVI.01345-10. View

Luxembourg A, Hannaman D, Wills K, Bernard R, Tennant B, Menne S . Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigens. Vaccine. 2008; 26(32):4025-33. DOI: 10.1016/j.vaccine.2008.05.021. View

Atasheva S, Fish A, Fornerod M, Frolova E . Venezuelan equine Encephalitis virus capsid protein forms a tetrameric complex with CRM1 and importin alpha/beta that obstructs nuclear pore complex function. J Virol. 2010; 84(9):4158-71. PMC: 2863722. DOI: 10.1128/JVI.02554-09. View

Phillpotts R, Jones L, Howard S . Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine. 2002; 20(11-12):1497-504. DOI: 10.1016/s0264-410x(01)00505-9. View

Kortepeter M, Cieslak T, Eitzen E . Bioterrorism. J Environ Health. 2001; 63(6):21-4. View

Reisler R, Gibbs P, Danner D, Boudreau E . Immune interference in the setting of same-day administration of two similar inactivated alphavirus vaccines: eastern equine and western equine encephalitis. Vaccine. 2012; 30(50):7271-7. DOI: 10.1016/j.vaccine.2012.09.049. View

Gurunathan S, Klinman D, Seder R . DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol. 2000; 18:927-74. DOI: 10.1146/annurev.immunol.18.1.927. View

Roy C, Adams A, Wang E, Leal G, Seymour R, Sivasubramani S . A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus. Vaccine. 2013; 31(11):1464-70. PMC: 3581708. DOI: 10.1016/j.vaccine.2013.01.014. View

MATHEWS J, Roehrig J, TRENT D . Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J Virol. 1985; 55(3):594-600. PMC: 255017. DOI: 10.1128/JVI.55.3.594-600.1985. View

10.

FRANZ D, Jahrling P, McClain D, Hoover D, Byrne W, Pavlin J . Clinical recognition and management of patients exposed to biological warfare agents. Clin Lab Med. 2001; 21(3):435-73. View

11.

Brooke C, Deming D, Whitmore A, White L, Johnston R . T cells facilitate recovery from Venezuelan equine encephalitis virus-induced encephalomyelitis in the absence of antibody. J Virol. 2010; 84(9):4556-68. PMC: 2863737. DOI: 10.1128/JVI.02545-09. View

12.

McClain D, Pittman P, RAMSBURG H, Nelson G, Rossi C, Mangiafico J . Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis. 1998; 177(3):634-41. DOI: 10.1086/514240. View

13.

Gauci P, Wu J, Rayner G, Barabe N, Nagata L, Proll D . Identification of Western equine encephalitis virus structural proteins that confer protection after DNA vaccination. Clin Vaccine Immunol. 2009; 17(1):176-9. PMC: 2812089. DOI: 10.1128/CVI.00377-09. View

14.

Garmashova N, Gorchakov R, Volkova E, Paessler S, Frolova E, Frolov I . The Old World and New World alphaviruses use different virus-specific proteins for induction of transcriptional shutoff. J Virol. 2006; 81(5):2472-84. PMC: 1865960. DOI: 10.1128/JVI.02073-06. View

15.

Nagata L, Hu W, Masri S, Rayner G, Schmaltz F, Das D . Efficacy of DNA vaccination against western equine encephalitis virus infection. Vaccine. 2005; 23(17-18):2280-3. DOI: 10.1016/j.vaccine.2005.01.032. View

16.

Taguchi T, McGhee J, Coffman R, Beagley K, Eldridge J, Takatsu K . Detection of individual mouse splenic T cells producing IFN-gamma and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. J Immunol Methods. 1990; 128(1):65-73. DOI: 10.1016/0022-1759(90)90464-7. View

17.

Bartelloni P, MCKINNEY R, Calia F, RAMSBURG H, COLE Jr F . Inactivated western equine encephalomyelitis vaccine propagated in chick embryo cell culture. Clinical and serological evaluation in man. Am J Trop Med Hyg. 1971; 20(1):146-9. DOI: 10.4269/ajtmh.1971.20.146. View

18.

MCKINNEY R, BERGE T, SAWYER W, TIGERTT W, Crozier D . USE OF AN ATTENUATED STRAIN OF VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS FOR IMMUNIZATION IN MAN. Am J Trop Med Hyg. 1963; 12:597-603. DOI: 10.4269/ajtmh.1963.12.597. View

19.

Dupuy L, Richards M, Reed D, Schmaljohn C . Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine. 2010; 28(46):7345-50. DOI: 10.1016/j.vaccine.2010.09.005. View

20.

Calisher C . Medically important arboviruses of the United States and Canada. Clin Microbiol Rev. 1994; 7(1):89-116. PMC: 358307. DOI: 10.1128/CMR.7.1.89. View